Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
- Resource Type
- Article
- Source
- The Lancet Gastroenterology & Hepatology; June 2019, Vol. 4 Issue: 6 p454-465, 12p
- Subject
- Language
- ISSN
- 24681253